Preclinical and clinical development of the innovative PI3 delta kinase inhibitor as a candidate in the treatment of inflammatory diseases

Funding Agreement No.: POIR.01.02.00-00-0085/18-00 under Measure 1.2: “Sectoral R&D programmes”
Date of the contract conclusion: 21/03/2019

The aim of the project is preclinical development and clinical evaluation of the innovative PI3 delta kinase inhibitor (phosphatidylinositide 3-kinase). The proposed inhibitor will be developed in the direction of the indication for the treatment of immunological and inflammatory diseases selected during preclinical development. The PI3K kinase belongs to the lipid kinase family. The delta isoform is specific to the cells of the immune system (Ito K. et al. (2007). J Pharmacol Exp Ther). It is assumed that blocking the signal amplified by PI3K delta may have a significant immunosuppressive effect.

The PI3K delta inhibitor created as a result of the works conducted within the project will be innovative in the Polish and world market in terms of its therapeutic purpose and low toxicity, as well as the observed adverse effects. The PI3K delta inhibitor available on the market has been developed especially to treat oncological diseases and its high toxicity makes it impossible to use it in the treatment of inflammatory diseases. The clinical trials on new PI3K delta inhibitors are also concentrated on oncological diseases. Only some of the substances are tested for their efficacy in the treatment of inflammatory diseases, namely Sjorgen syndrome. None of these treatments, unlike our molecule, is being developed to treat psoriasis, rheumatoid arthritis or systemic lupus erythematosus. For this reason, the development of a drug would constitute a worldwide innovation in terms of its therapeutic purpose.

Total value of the KICHAI project: PLN 39,824,650.00
Total value of funding: PLN 24,516,387.51